Last updated on June 2020

Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: PEAGE

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pulmonary Disease | Pulmonary Embolism | Lung Disease | Anticoagulants | Aged
  • Age: Between 75 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Symptomatic pulmonary embolism confirmed by objective paraclinical examination with or without DVT associated
  • confirmation of pulmonary embolism within 3 days
  • Administration possible according to the recommended dosages of anticoagulant treatment : (unfractionnated and low molecular weight heparins, fondaparinux, vitamin K antagonists and direct oral anticoagulants)
  • Indication of anticoagulant treatment for at least 6 months

Exclusion Criteria:

  • on therapeutic dose of anticoagulant treatment over 72 hours
  • indication to therapeutic dose of anticoagulant treatment for another reason.
  • Inability for whatever reasons, to prescribe recommended anticoagulant treatment
  • PE treatment on heparin-induced thrombocytopenia requiring argatroban, lepirudin or danaparoid treatment,
  • ongoing bleeding
  • PE occurring despite well conducted anticoagulant treatment
  • Contraindications to recommended dose of anticoagulant treatment

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.